Eikon Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Eikon Therapeutics reported a larger 2025 net loss while advancing its oncology pipeline, closing a $349M IPO in February 2026 and guiding cash runway into 2H 2027 despite a disclosed material weakness and a license dispute.